MKNK1 and Alzheimer disease: Given that our data suggest that CYFIP2 reduction by Aβ1-42 can be blocked by Mnk1 inhibition, and CYFIP2 reduction results in age-dependent AD-like pathology in the mouse brain, we propose Mnk1 as a therapeutic target in AD.